This article is part of the supplement: The evolution of anti-TNF therapy in rheumatic disease: experience, insights and advances
Review
Infliximab: 12 years of experience
Arthritis Research & Therapy 2011, 13(Suppl 1):S2 doi:10.1186/1478-6354-13-S1-S2
No comments have yet been made on this article.
